South Korea Pharmacovigilance and Drug Safety Software Market Size, Share, Growth, and Industry Analysis, By Software Type (Adverse Event Reporting Software, Drug Safety Data Management Software, Signal Detection Software, Risk Management Software), By Delivery Mode (On-Premise Software, Cloud-Based Software, Web-Based Software) and Forecast, 2026-2034

South Korea Pharmacovigilance and Drug Safety Software Market Trends

AI-Enabled Safety Automation and Digitized Case Processing

Pharmacovigilance technology is shifting from rules-based case databases toward AI-assisted intake, narrative generation, signal prioritization, and automated event detection. ArisGlobal reported that one 2025 deployment covered approximately 20,000 safety cases annually, while its Advanced Signals platform reported up to 80% faster signal assessment. The company also recorded 27 go-lives during H1 2025 and 7 global pharmaceutical companies using NavaX in safety operations, illustrating the expanding production-scale deployment of automated safety workflows.

South Korea's digital pharmacovigilance environment is reinforced by KAERS, which supports electronic adverse-event collection and subsequent signal detection, assessment, and safety-information generation. The MFDS also issued digital medical-device software guidance on May 7, 2025, demonstrating continued regulatory formalization of software-based healthcare systems. Globally, IQVIA reported that GenAI-enabled Vigilance Detect can produce up to 80% fewer false positives in cited client applications, increasing the relevance of AI-supported review for high-volume safety operations.

South Korea Pharmacovigilance and Drug Safety Software Market Drivers

Rising Regulatory Data Complexity Accelerates Safety-System Modernization

The requirement to process expanding structured and unstructured safety information is pushing pharmaceutical companies and CROs toward integrated platforms. Modern systems must manage 1st and follow-up reports, patient and medicine information, attachments, assessment workflows, and regulatory records within controlled environments; KAERS itself provides structured individual-report functionality across these data classes. Internationally, deployments processing approximately 20,000 cases annually and technologies delivering up to 80% faster signal assessment demonstrate the operational scale driving automation investments.

South Korea Pharmacovigilance and Drug Safety Software Market Restraints

Validation, Migration and Governance Requirements Raise Implementation Burden

Safety-platform replacement requires validated migration, user retraining, data-quality controls, cybersecurity, and regulatory governance. A single enterprise environment can process tens of thousands of cases annually, making even a 1% data-quality exception rate operationally significant. AI additionally introduces model-governance requirements: despite solutions reporting up to 80% reductions in false positives or 80% faster signal assessment, regulated organizations still require reviewability, traceability, and human oversight before automated outputs enter safety decisions.

South Korea Pharmacovigilance and Drug Safety Software Market Opportunities

Generative AI Creates Scope for Higher-Productivity Safety Operations

Generative AI offers opportunities in case intake, data extraction, narrative generation, literature review, and signal workflows. In December 2025, ArisGlobal reported a 17% case-intake efficiency improvement within 3 weeks of a NavaX deployment, while another safety solution reported 80% faster signal assessment. With 7 global pharmaceutical companies already using NavaX during H1 2025, scalable automation is moving beyond pilot programs toward enterprise production environments.

Challenges in South Korea Pharmacovigilance and Drug Safety Software Market

Interoperability and Explainable Automation Remain Critical

Organizations must connect safety databases with EHR, EDC, CRO, regulatory, medical-information, and analytics systems while maintaining auditability. A platform may process 20,000 cases annually across 3 major geographic regions, creating substantial reconciliation requirements when source formats differ. Meanwhile, AI systems claiming up to 80% fewer false positives still require explainable findings and controlled human review, making governance and interoperability central technical challenges.

South Korea Pharmacovigilance and Drug Safety Software Market Segmentation

The industry is segmented by software type, delivery mode, functionality, and end user. In 2026, Adverse Event Reporting Software accounts for approximately 31.58% of the USD 58.65 million software-type total, while On-Premise Software represents approximately 50.81% of the USD 58.69 million delivery-mode total. The USD 0.04 million difference between supplied 2026 totals is retained because the two mandatory source tables report separate totals.

By Software Type

Adverse Event Reporting Software is the largest category, increasing from USD 16.98 million in 2025 to USD 18.52 million in 2026 and USD 37.03 million by 2034, at a 9.05% CAGR. Its approximately 31.58% 2026 contribution reflects the central role of intake, case processing, follow-up, and adverse-event submission.

EDC and Analytics Integration Tools are the fastest-growing category at 9.86% CAGR, rising from USD 3.07 million in 2026 to USD 6.50 million in 2034. Drug Safety Data Management Software follows at 9.78%, Regulatory Compliance Software at 9.56%, Risk Management Software at 9.01%, and Signal Detection Software at 8.97%.

By Delivery Mode

On-Premise Software leads with USD 29.82 million in 2026 and is forecast to reach USD 61.45 million in 2034, registering 9.46% CAGR. It represents approximately 50.81% of the supplied USD 58.69 million delivery-mode total, reflecting continued preference for controlled enterprise deployments.

Web-Based Software is the fastest-growing delivery category at 9.62% CAGR, expanding from USD 10.99 million in 2026 to USD 22.92 million by 2034. Cloud-Based Software rises from USD 17.88 million to USD 35.74 million at 9.04% CAGR, indicating sustained demand for externally hosted safety infrastructure.

By Functionality

Functionality spans 6 areas: Case Data Entry and Processing, Signal Detection and Management, Benefit-Risk Evaluation, Submission to Regulatory Authorities, Data Integration, and Analytics and Dashboards. No functionality-level market values or CAGR figures were supplied; consequently, numerical allocation of the USD 58.65 million 2026 total across these 6 functions is not inferred.

By End User

Demand is distributed across 5 end-user groups: pharmaceutical and biotechnology companies, CROs, regulatory agencies, BPO firms, and hospitals and healthcare providers. The supplied dataset establishes an overall 2026 value of USD 58.65 million and 9.37% CAGR but provides no end-user revenue split; therefore, individual percentages are intentionally not fabricated.

South Korea Pharmacovigilance and Drug Safety Software Market Counties Outlook

South Korea is the sole country geography in this study, representing 100% of the report's geographic scope. The national market progresses from USD 53.68 million in 2025 to USD 58.65 million in 2026 and USD 119.21 million in 2034 based on the software-type dataset, equivalent to 9.37% CAGR. Seoul, Gyeonggi, Incheon, Busan, Daejeon, and other subnational areas participate in Korea's pharmaceutical and healthcare ecosystem, but no county-level production, contribution, or sector-split values were supplied; therefore, regional percentages beyond the national 100% scope are not estimated.

Top players in South Korean pharmacovigilance and drug safety software market

1. Oracle Corporation
2. ArisGlobal
3. IQVIA
4. Veeva Systems
5. Ennov
6. Extedo
7. AB Cube
8. ClinChoice
9. ICON plc
10. Parexel International
11. Accenture
12. Cognizant
13. Wipro
14. Tata Consultancy Services
15. Laboratory Corporation of America Holdings

Top Two Companies

• Oracle Corporation:Oracle is positioned around Argus, an enterprise pharmacovigilance platform supporting case management and safety operations. In July 2025, PrimeVigilance adopted Oracle Argus to strengthen pharmacovigilance data management, accuracy, automation, and regulatory compliance. The South Korean competitive-share percentage of Oracle is not disclosed in the supplied dataset, so no unsupported percentage is assigned. Against a national 2026 market baseline of USD 58.65 million and a 9.37% forecast CAGR, Oracle competes for enterprise pharmaceutical, biotechnology, and CRO workloads requiring scalable case processing and regulated safety-data management.
• ArisGlobal:ArisGlobal competes through LifeSphere Safety and NavaX automation across case management, reporting, analytics, and signal detection. During H1 2025, the company recorded 27 go-lives, with 7 global pharmaceutical organizations using NavaX and APAC implementations increasing 233% year over year to 10. Another deployment handled approximately 20,000 safety cases annually. No verified South Korea-specific company-share percentage is available in the supplied tables, preventing a defensible numerical share estimate. Its positioning is nevertheless strengthened by multi-tenant cloud delivery, AI automation, multilingual reporting, and expanding APAC implementation activity.

Recent Developments in South Korea's Pharmacovigilance and Drug Safety Software Market

• 2025: ArisGlobal introduced LifeSphere Unify, NavaX Insights, and Advanced Compliance Docs on March 19, expanding AI-enabled pharmacovigilance and regulatory capabilities.
• 2025: ArisGlobal announced an Advanced Signals deployment on April 10, reporting up to 80% faster signal assessment.
• 2025: Oracle announced on July 8 that PrimeVigilance was using its AI-powered Argus platform for pharmacovigilance operations.
• 2025: ArisGlobal reported 27 go-lives during H1, 7 global pharmaceutical NavaX users, and 233% year-over-year expansion to 10 APAC implementations.
• 2025: IQVIA introduced evidence around GenAI-enabled Vigilance Detect, reporting up to 80% fewer false positives in cited client applications and emphasizing explainable safety-event detection.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, historical context covering 2022–2024, and a forecast horizon of 2026–2034. Mandatory supplied tables are the primary quantitative source: USD 53.68 million in 2025, USD 58.65 million in 2026, USD 119.21 million in 2034, and 9.37% CAGR are retained for the principal software-type series. Segment percentages are calculated directly from supplied values, while external regulatory and company sources are used only for qualitative technology, operational, and development context. No unsupported regional, end-user, functionality, or company-share figures have been fabricated.